Last $31.56 USD
Change Today 0.00 / 0.00%
Volume 0.0
PHGFF On Other Exchanges
Symbol
Exchange
New York
EN Amsterdam
OTC US
Xetra
BrsaItaliana
EN Amsterdam
As of 8:10 PM 07/18/14 All times are local (Market data is delayed by at least 15 minutes).

koninklijke philips nv (PHGFF) Snapshot

Open
$31.27
Previous Close
$31.56
Day High
$31.56
Day Low
$31.25
52 Week High
01/21/14 - $38.07
52 Week Low
06/26/14 - $29.85
Market Cap
30.2B
Average Volume 10 Days
13.6K
EPS TTM
--
Shares Outstanding
956.7M
EX-Date
05/5/14
P/E TM
--
Dividend
$0.83
Dividend Yield
3.52%
Current Stock Chart for KONINKLIJKE PHILIPS NV (PHGFF)

Related News

No related news articles were found.

koninklijke philips nv (PHGFF) Details

Koninklijke Philips N.V. is engaged in healthcare, consumer lifestyle, and lighting businesses worldwide. Its healthcare solutions include radiation oncology, clinical applications and platforms, and portfolio management; advanced diagnostic imaging, such as computed tomography (CT), magnetic resonance imaging (MRI), and molecular imaging; digital X-ray and mammography; interventional X-rays; ultrasound products; enterprise patient monitoring solutions for clinical information at the patient’s bedside; cardiology informatics and enterprise imaging informatics; patient monitoring and clinical informatics; mother and child care products; therapeutic care products; sleep management, respiratory care, and non-invasive ventilation; medical alert and medication dispensing services; remote patient monitoring; and equipment services and support, equipment financing and asset management, and professional services. The company's consumer lifestyle solutions consist of mother and childcare, oral healthcare, pain management, male grooming, and beauty products; and kitchen appliances, coffee, garment care, floor care, and air purification products. Its lighting solutions include light sources and electronics, such as LED, eco-halogen, fluorescent, discharge, and incandescent light sources, as well as electronic and electromagnetic gears, modules, and drivers; consumer luminaires, including functional, decorative, lifestyle, and scene-setting luminaires; professional lighting solutions, such as controls and luminaires for city beautification, road lighting, sports lighting, office lighting, shop/hospitality lighting, and industry lighting; automotive lighting products; and packaged LEDs. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

112,834 Employees
Last Reported Date: 07/21/14
Founded in 1891

koninklijke philips nv (PHGFF) Top Compensated Officers

Chief Executive Officer, Chairman of the Boar...
Total Annual Compensation: €2.2M
Chief Financial Officer, Executive Vice-Presi...
Total Annual Compensation: €1.2M
Executive Vice-President, Chief Executive Off...
Total Annual Compensation: €1.2M
Compensation as of Fiscal Year 2013.

koninklijke philips nv (PHGFF) Key Developments

Royal Philips Receives FDA 510(K) Clearance for its Innovative Ultra Mobile VISIQ Ultrasound System

Royal Philips announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its innovative ultra mobile ultrasound system, VISIQ, in the U.S. This breakthrough ultrasound device can be easily transported wherever care is needed, and its quick-start technology and long battery life make it an ideal system for physician offices, hospitals and other clinical settings. VISIQ's touch-screen gesture controls are familiar to anyone who has used a smartphone or tablet. It allows users to easily capture images, take measurements and share data. In addition, VISIQ offers many of the automatic image optimization features found on Philips' premium EPIQ system, as well as built-in Wi-Fi for DICOM data transfer to hospital or cloud-based PACS. At the heart of the VISIQ system is a smart transducer that fits comfortably into the user's hand. Drawing on more than 30 years of experience in ultrasound, Philips has taken advantage of advances in miniaturization to integrate a sophisticated broadband micro-digital beam former and powerful image acquisition module into the transducer. VISIQ targets OB and abdominal applications and lays the foundation for a future range of portable ultrasound products to meet the evolving needs of clinicians and patients.

The Christie NHS Foundation Trust Joins Elekta and Philips Research Consortium to Develop MRI-Guided Radiation Therapy System for Cancer Treatment

Elekta and Royal Philips announced that The Christie NHS Foundation Trust (Manchester, UK) will join a consortium whose mission is to develop the clinical value of an integrated magnetic resonance imaging (MRI) guided radiation therapy system. Such a system would, in principle, improve the practice of radiotherapy via real-time visualization of cancer targets. The Christie is the seventh member to join the research consortium that assesses the novel technology, which brings together radiation therapy and MRI in a single system. The consortium also includes the University Medical Center Utrecht (Utrecht, the Netherlands), The University of Texas MD Anderson Cancer Center (Houston, Texas), The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (Amsterdam, the Netherlands), Sunnybrook Health Sciences Centre (Toronto, Ontario), The Froedtert & Medical College of Wisconsin Cancer Center (Milwaukee, Wisconsin) and The Institute of Cancer Research, working with its clinical partner The Royal Marsden NHS Foundation Trust (London, England). The Christie joined the recent research consortium meeting at Utrecht, where the clinical indications that would benefit the most from the use of MRI-guided radiation therapy were discussed. These targets are typically going to be in anatomy that changes its position and shape either from day to day or during the treatment. The consortium anticipates that the use of MRI imaging at the time of treatment will result in a considerable increase in the accuracy of the placement of the dose, reducing the need for large safety margins around the tumor target.

Koninklijke Philips N.V Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 29, 2014

Koninklijke Philips N.V reported unaudited consolidated earnings results for the second quarter and six months ended June 29, 2014. For the quarter, the company reported sales of EUR 5,293 million against EUR 5,632 million a year ago. EBITA was EUR 415 million against EUR 601 million a year ago. EBIT was EUR 332 million against EUR 507 million a year ago. Net income from continuing operations was EUR 220 million against EUR 322 million a year ago. Net income was EUR 243 million against EUR 317 million a year ago, the year on year decrease reflects lower operational results, partly offset by lower income tax expense. Net income attributable to shareholders per common share diluted was EUR 0.26 against EUR 0.35 per share a year ago. Net capital expenditures was EUR 226 million against EUR 246 million a year ago. Income from operations was EUR 332 million against EUR 507 million a year ago. Income before taxes was EUR 258 million against EUR 429 million a year ago. Net cash provided by operating activities was EUR 487 million against EUR 141 million a year ago. Purchase of intangible assets was EUR 21 million against EUR 6 million a year ago. Capital expenditures on property, plant and equipment was EUR 128 million against EUR 145 million a year ago. For the six months, the company reported sales of EUR 10,306 million against EUR 10,877 million a year ago. EBITA was EUR 730 million against EUR 1,004 million a year ago. EBIT was EUR 559 million against EUR 813 million a year ago. Net income from continuing operations was EUR 359 million against EUR 477 million a year ago. Net income was EUR 380 million against EUR 479 million a year ago. Net income attributable to shareholders per common share diluted was EUR 0.41 against EUR 0.52 per share a year ago. Net capital expenditures was EUR 399 million against EUR 450 million a year ago. Cash flow from operating activities was an inflow of EUR 310 million, compared to an outflow of EUR 86 million in the first half of 2013. Income from operations was EUR 559 million against EUR 813 million a year ago. Income before taxes was EUR 416 million against EUR 652 million a year ago. Net cash provided by operating activities was EUR 310 million against net cash used for operating activities of EUR 86 million a year ago. Purchase of intangible assets was EUR 32 million against EUR 8 million a year ago. Capital expenditures on property, plant and equipment was EUR 221 million against EUR 270 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHGFF:US $31.56 USD 0.00

PHGFF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bridgestone Corp ¥3,796 JPY +22.00
Canon Inc ¥3,409 JPY -5.00
Kimberly-Clark Corp $108.53 USD -0.96
Linde AG €152.56 EUR -1.45
Mitsubishi Electric Corp ¥1,365 JPY +6.50
View Industry Companies
 

Industry Analysis

PHGFF

Industry Average

Valuation PHGFF Industry Range
Price/Earnings 20.6x
Price/Sales 0.9x
Price/Book 2.0x
Price/Cash Flow 21.0x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KONINKLIJKE PHILIPS NV, please visit www.philips.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.